Indicated for: HIV-1 infection
Substance: emtricitabine + tenofovir (nucleoside/nucleotide reverse transcriptase inhibitors)
ATC: J05AR03 (Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations)
The combination of emtricitabine and tenofovir is used for the treatment of human immunodeficiency virus (HIV) infection and for pre-exposure prophylaxis (PrEP) in individuals at high risk of infection. These drugs work by inhibiting reverse transcriptase, an enzyme essential for HIV replication.
The medication is taken orally, usually once daily, with the dose adjusted based on the patient's weight and renal function. Common side effects include nausea, diarrhea, headaches, and fatigue.
This combination is contraindicated in patients with severe renal impairment or hypersensitivity to any of the components. Its use also requires regular monitoring of renal and hepatic function.
This medication is an important option for managing HIV infection and preventing virus transmission, helping to improve patients' quality of life.